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Summary line: In epidemiological surveillance, prevalence of current SARS-CoV-2 infection 
by nucleic acid detection was 27.7% and 7.2% among farmworkers in Monterey County, 
California, with and without potential COVID-19 symptoms, underscoring high risk of infection 
in this essential workforce population. 
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ABSTRACT—148 words 
As essential personnel, United States farmworkers have continued working in-person throughout 
the COVID-19 pandemic. We undertook prospective surveillance of SARS-CoV-2 infection and 
antibody prevalence among farmworkers in California’s Salinas Valley from 15 June to 30 
November, 2020. Over this period, we observed 22.1% (1514/6864) positivity for current SARS-
CoV-2 by nucleic acid detection among farmworkers tested at federally-qualified migrant and 
community health clinics, as compared to 17.2% (1255/7305) among other adults from the same 
communities (risk ratio, 1.29; 95% confidence interval, 1.20-1.37). In a nested study enrolling 
1,115 farmworkers, prevalence of current infection was 27.7% among farmworkers reporting ≥1 
potential COVID-19 symptom, and 7.2% among farmworkers without symptoms (adjusted odds 
ratio 4.16; 2.85-6.06). Prevalence of anti-SARS-CoV-2 IgG antibodies increased from 10.5% 
(6.0-18.4%) between 16 July-31 August to 21.2% (16.6-27.4%) between 1-30 November. The 
high observed prevalence of infection among farmworkers underscores the need for vaccination 
and other preventive interventions. 
 
MAIN TEXT—3,395 words 
 
INTRODUCTION 
In response to the ongoing coronavirus disease 2019 (COVID-19) pandemic, the United 
States and other countries have implemented broad interventions aiming to mitigate community 
transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1). Workers in 
food production and other industries deemed essential to continuity of public health and safety 
have continued in-person work (2). While COVID-19 outbreaks have been reported among 
various essential workforce groups, including employees in food processing facilities (3, 4), to 
date no studies have prospectively assessed risk of infection among essential workers involved in 
food production. 
Agriculture and related food production industries comprise one of the lowest-paid 
sectors of the US economy, with 29% of full-time workers earning an annual income below 
$12,760 as individuals or $26,200 for a family of four (5). Agriculture in particular draws on a 
predominantly Latino immigrant workforce (6), who in comparison to their US-born 
counterparts work longer hours, receive lower wages, and experience higher levels of household 
poverty (7). An estimated 54% of immigrant farmworkers are undocumented, and thus have 
reduced access to federal benefits under the Coronavirus Aid, Relief, and Economic Security Act 
(8). These circumstances have compounded pre-existing legal and economic challenges faced by 
farmworkers during the COVID-19 pandemic (9, 10). 
We initiated surveillance of SARS-CoV-2 infection among farmworkers in California’s 
Salinas Valley to monitor the epidemic. We have previously described impacts of the pandemic 
on economic well-being, mental health, and food insecurity within this population (11). Here we 
report on the prevalence of SARS-CoV-2 infection among farmworkers tested from June to 
November, 2020, as well as symptoms and antibody responses within a subset of these 





The Salinas Valley is a 90-mile stretch of agricultural land within Monterey County, 
California; prominent farmed crops include leafy greens, berries, broccoli, artichokes, and wine 
grapes. The agricultural workforce comprises ~50,000 resident farmworkers, with an additional 
40,000 seasonal workers supporting the peak summer and fall seasons (12). The population is 
75% Latino, and 30-60% of workers are believed to be undocumented (13). Severe 
overcrowding and household disrepair are common among farmworkers (14), with many living 
in multi-generational households (15) as well as labor camps, vehicles, and informal dwellings 
(16). Many farmworkers travel long distances to work, often in shared trucks or buses, and may 
work in close proximity to one another. These circumstances have led to concern about difficulty 
preventing SARS-CoV-2 transmission among farmworkers and in their communities (17). 
We undertook this study in partnership with Clínica de Salud del Valle de Salinas 
(CSVS), a federally-qualified community and migrant health center in Monterey County. As the 
main healthcare provider for the region’s farmworkers and their families, CSVS operates a 




Testing for SARS-CoV-2 infection at CSVS clinics began 15 June, 2020, and was offered 
to all individuals at clinics during weekday business hours. Medical personnel collected 
oropharyngeal specimens for detection of SARS-CoV-2 RNA via the qualitative Hologic 
(Marlborough, Massachusetts) Aptima nucleic acid transcription-mediated amplification (TMA) 
assay (analytical sensitivity: 62.5 RNA transcript copies/mL (18); clinical specificity: 99.9% 
(19)). All patients receiving care from CSVS for any reason were encouraged by their healthcare 
providers to receive SARS-CoV-2 testing, regardless of symptoms; testing was also made 
available to individuals who were not CSVS patients. No-cost testing for individuals without 
insurance was supported by funding from the Health Resources and Services Administration. 
Additionally, CSVS conducted outreach testing via mobile testing facilities at community sites 
including low-income and employer-provided housing, agricultural fields, homeless shelters, 
food banks, and CSVS-run health fairs where free SARS-CoV-2 testing was offered alongside 
seasonal influenza vaccination and food donations.  
 
Clinical surveillance study 
As part of routine clinical intake, all patients ages ≥18 years were asked about 
employment. We considered farmworkers to include all persons engaged in work in agriculture, 
including but not limited to crop, nursery, and greenhouse laborers; agricultural equipment 
operators; workers in packing sheds and other food processing facilities; and farm and ranch 
animal workers and breeders. 
 
Cross-sectional study 
Enrollment: To better understand the distribution, dynamics, and clinical profile of infection in 
among farmworkers, we invited farmworkers who were receiving a SARS-CoV-2 TMA test at 
CSVS to participate in a more in-depth cross-sectional study further entailing anti-SARS-CoV-2 
antibody testing and a detailed questionnaire. To advertise the cross-sectional study, Spanish- 
and English-language fliers were distributed in the community and to area growers and were 
hung in clinics describing the opportunity to receive free SARS-CoV-2 testing from CSVS and 
participate in the study. The study team was stationed at CSVS testing facilities and aimed to 
approach all patients receiving SARS-CoV-2 TMA tests to screen for study eligibility and invite 
participation in the cross-sectional study. When time allowed, study personnel called patients 
with scheduled SARS-CoV-2 testing appointments at CSVS on the day before their visit to 
advertise the study and screen for eligibility. Participants in an ongoing longitudinal study of 
farmworker families (13) and those living in housing for farmworkers were also invited to 
participate and to bring other farmworkers.  
Eligible participants were non-pregnant adult farmworkers ages ≥18 years receiving 
SARS-CoV-2 TMA testing at CSVS who had conducted farm work ≤14 days before their testing 
date, who had not previously participated, and who spoke sufficient English or Spanish to give 
consent and complete study procedures. To accommodate the end of the growing season, from 5 
October onward we enrolled individuals who had engaged in farm work any time since March 
2020.  
Study procedures: The study team obtained a blood sample by venipuncture and measured 
participants’ height and weight using large-print tape measures adhered to a post or wall and 
digital scales. Within 48 hours before (for pre-consented participants) or after the enrollment 
visit, and before SARS-CoV-2 testing results were available, the study team administered a 45-
minute computer-guided questionnaire by telephone in Spanish or English. Questionnaire items 
addressed participant demographics, socio-economic status, symptoms since December 2019 and 
in the two weeks preceding enrollment, COVID-19 risk factors and exposures, and impacts of 
the pandemic on daily life and wellbeing (11, 20). Following completion of all components of 
the study, the study team loaded a $50 incentive onto VISA gift cards handed out to participants 
at the enrollment visit. 
Blood specimens were stored immediately at 4-7ºC and centrifuged ≤48 hours after 
collection. Following separation, plasma aliquots were heat-inactivated at 56°C for 30 minutes 
and stored at –80ºC, then used for assessment of immunoglobulin G (IgG) reactivity against the 
SARS-CoV-2 spike protein via in-house enzyme linked immunosorbent assays (ELISAs) (21). 
Briefly, recombinant full-length SARS-CoV-2 spike protein (John Pak, Chan Zuckerberg 
Biohub) was coated on Nunc Maxisorp ELISA plates (Themofisher) at 1.5µg/mL. Plates were 
blocked with 2.5% non-fat dry milk in 1X phosphate-buffered saline (PBS) for 2 hours at 37°C. 
Plates were then washed 3 times in 1X PBS. Plasma samples, diluted 1:100 in 1% non-fat dry 
milk in 1X PBS, were added to the plate in duplicate wells. After a 1-hour incubation at 37°C, 
plates were washed 5 times in 1X PBS + 0.05% Tween-20. Bound anti-spike IgG was detected 
using horseradish peroxidase-conjugated goat-anti-human IgG antibody (Fisher Scientific). The 
plate was developed using a 3,3′,5,5′-Tetramethylbenzidine (TMB) solution, and the reaction 
was stopped with 2M H2SO4 after 6 minutes. Prior assay validation was performed using 
convalescent (≥8 days post-onset) serum samples from 60 hospitalized, PCR-confirmed COVID-
19 cases; 57 mild or subclinical PCR-confirmed COVID-19 cases; and 131 unexposed 
individuals (pre-2020 serum samples). Specimens were considered to be positive for anti-SARS-
CoV-2 spike IgG if the ELISA optical density (OD) value was >0.096. This cutoff maximized 
area under the receiver operating characteristic curve, yielding 94.0% sensitivity and 98.5% 
specificity. All specimens were processed in duplicate; reflex testing was conducted if ≥1 OD 
measurement fell in the borderline range of 0.07-0.3 or if the coefficient of variation between 
replicates was ≥30% and ≥1 OD measure was ≥0.07. All specimens considered positive by the 
spike ELISA were confirmed by presence of IgG against the receptor binding domain (RBD) of 
SARS-CoV-2 spike protein (John Pak, Chan-Zuckerberg Biohub), using the protocol described 
above, substituting the coating antigen with RBD at 3ug/mL. Specimens were considered 
positive if RBD ELISA OD values were >0.205, determined via a similar validation process as 
described above for spike protein. 
 
Statistical analyses 
Clinical surveillance study: Results for all patients tested at CSVS from 15 June through 30 
November, 2020 were tabulated by age, sex, and farmworker status. We also computed 2-week 
moving averages in the daily proportion of tests yielding positive results as well as estimates of 
the final proportion of tests yielding positive results by patient age, sex, and farmworker status. 
We used the Beta distribution to define 2.5% and 97.5% quantiles for the proportion positive. 
Cross-sectional study: We computed adjusted odds ratios (aORs) using logistic regression 
models accounting for age, sex, and venue to determine the association of symptoms 
(experienced in the last two weeks) with a positive test result. We used the same logistic 
regression framework to estimate aORs for the association of each symptom (experienced in the 
prior two weeks or at any time since December, 2019) with anti-SARS-CoV-2 antibody OD 
measures (continuous).  
We computed stabilized sampling weights (22) to correct for differences in the 
population enrolled in the study over time when estimating prevalence of infection. To generate 
weights for each recruitment period (16 July-31 August, 1-30 September, 1-31 October, or 1-30 
November), we fit a multinomial logistic regression model which included all exposures listed in 
Table 1, the number of symptoms participants reported in the preceding two weeks, and the 
recruitment venue as predictors. 
We estimated period-specific prevalence of SARS-CoV-2 infection and of seropositivity, 
accounting for inverse sampling weights, using a generalized linear model with a log-binomial 
link function. Models accounted for the four recruitment periods above, presence of any 
symptoms, and recruitment venue. We used the model parameter estimates to summarize period-
specific prevalence of TMA-positive and seropositive status for individuals with and without 
symptoms, whom we would have expected to reach via community outreach. To account for 
missing data (1.1% of observations across all outcome and predictor variables), we sampled 
estimates from five independent iterations of the analysis carried out on multiply-imputed 
datasets. Analyses were conducted in R (version 4.0.3); we used the Amelia II package (23) for 




Clinical surveillance study 
Between 15 June and 30 November, CSVS administered 14,169 SARS-CoV-2 TMA tests 
to adults, including 6,864 tests among farmworkers and 7,305 among other adults living in the 
same communities (Figure 1A). In total, 1,514 tests among farmworkers (22.1%) had positive 
results, as compared to 1,255 (17.2%) among other adults, corresponding to a 28.5% (95% 
confidence interval: 20.1-37.4%) higher probability of positive test results among farmworkers 
(Figure 1B-C). The test-positive fraction was similarly higher among men than among women 
both among farmworkers (23.7%, men vs. 20.5%, women; risk ratio: 1.16, 1.06-1.27) and non-
farmworkers (21.7%, men vs. 18.8%, women; risk ratio: 1.15, 1.09-1.23). Point estimates of the 
test-positive fraction were consistent with equal or higher prevalence of infection among 
farmworkers across all age and sex strata (Figure 1D-E). 
Among farmworkers, multiple peaks in the proportion of TMA tests yielding positive 
results were evident, with the moving average of the test-positive fraction reaching 32.0% (27.2-
37.0%) and 30.4% (27.0-34.0%) over the two-week periods surrounding 30 June and 14 August, 
respectively (Figure 1C). After declining from mid-September to early October, both the 
number of tests and the proportion yielding positive results increased through the remainder of 
the study period; from 10 October to 23 November, the two-week moving average of the number 
of tests conducted daily increased from 35.5 to 69.5 among farmworkers and from 38.7 to 104.5 
among other adults; the proportion positive increased from 15.4% (12.2-18.8%) to 22.7% (20.0-
25.5%) among farmworkers and from 12.1% (9.4-15.1%) to 19.9% (17.9-22.1%) among other 
adults. This increase in case volume among non-farmworker adults in November, without a 
commensurate rise among farmworkers, coincided with the annual migration of many Salinas 
Valley farmworkers to Yuma, Arizona and elsewhere (25). 
 
Cross-sectional study 
Our cross-sectional study recruited 1,115 farmworkers, including 565 who were tested at 
clinics and 550 tested via outreach (Figure 2). SARS-CoV-2 TMA test results were obtained for 
1,111 (99.6%) of these individuals, and ELISAs were conducted for 1,058 (94.9%; Table 1). 
Most of the farmworkers in this study were born in Mexico, spoke Spanish at home, had primary 
school-level education or less, earned <$25,000 per year, and worked in the fields; 36.3% lived 
in crowded housing. Most (81.8%) were overweight or obese, and only 4.4% were current 
smokers. In comparison to farmworkers recruited via outreach, farmworkers recruited at clinics 
had lower levels of educational attainment and a shorter length of stay in the US; a higher 
proportion spoke indigenous languages at home (14.9% vs. 4.7%) and reported contact with an 
individual experiencing respiratory symptoms (17.9% vs. 3.3%). 
Overall, 27.2% of participants reported symptoms potentially related to COVID-19 in the 
last two weeks and 41.2% reported symptoms since the start of the pandemic. A higher 
proportion of farmworkers recruited at clinics compared to those recruited via outreach reported 
at least one symptom potentially attributable to COVID-19 in either the two weeks before testing 
(35.8% vs. 18.4%; Table 1) or the period since December 2019 (47.7% vs. 34.7%). A total of 
12.7% of all farmworkers tested TMA-positive for current SARS-CoV-2 infection, including 
18.7% of farmworkers tested at clinics and 6.6% of those tested via outreach (Table 1). In 
contrast, 19.0% of farmworkers tested via ELISA were found to have antibody evidence of prior 
infection, with similar prevalence among those tested in the clinics (18.4%) and via outreach 
(19.4%). 
Of all farmworkers who tested TMA-positive, 58.9% reported symptoms in the preceding 
two weeks, including 64.8% among those recruited from the clinic and 41.7% of those recruited 
via outreach (Table 2). Overall, 27.2% of those who had any potential COVID-19 symptoms in 
the two weeks prior to enrollment had current TMA-positive SARS-CoV-2 infection. Prevalence 
of current infection among farmworkers recruited in the clinic was 34.2% and 10.1% for those 
reporting any symptoms and no symptoms, respectively. Among farmworkers recruited from 
outreach testing, current TMA-positive SARS-CoV-2 infection was detected in 14.9% and 4.7% 
of those reporting any symptoms and no symptoms, respectively. Following adjustment for age, 
sex, and recruitment setting, the adjusted odds ratio (aOR) of a TMA-positive SARS-CoV-2 test 
result was 4.16 (2.85-6.06) among farmworkers reporting any of the solicited symptoms in the 
past two weeks versus those reporting no symptoms (Figure 3). Symptoms most strongly 
associated with current SARS-CoV-2 infection included shortness of breath (aOR: 26.86; 8.78-
83.31), loss of smell (aOR: 14.06; 6.37-31.15), loss of taste (aOR: 11.62; 5.52-24.77), and self-
reported fever (aOR: 9.06; 5.02-16.39). Each of these symptoms, however, was reported by 
<25% of individuals with current SARS-CoV-2 infection. The most commonly reported 
symptoms among individuals testing positive, headache (33.0%) and myalgia (31.6%), were 
associated with 3.52 (2.31-5.33) and 6.13 (3.83-9.77) fold higher adjusted odds of SARS-CoV-2 
RNA detection, respectively. 
Individuals who recalled experiencing a blocked nose, sweating, chills, headache, a 
tickling sensation in the throat, a feeling of pain or pressure in the sinuses, loss of appetite, 
shortness of breath, fatigue, a loss of taste, a loss of smell since December 2019 had higher 
antibody reactivity, on average, than individuals who did not recall experiencing such symptoms 
(Figure 4A). We also identified higher antibody reactivity among individuals experiencing 
wheeze or loss of taste in the preceding two weeks, as well as suggestive associations of higher 
antibody measurements with chest pain and loss of smell in the preceding two weeks (Figure 
4B). Quantitative antibody reactivity measures were not found to differ significantly among 
individuals who were or were not currently infected with SARS-CoV-2 (p=0.3), suggesting 
associations of antibody reactivity with recent symptoms were not attributable to current 
infection; 30 of 129 TMA-positive individuals (18%) and 168 of 925 TMA-negative individuals 
(23%) met the threshold for IgG seropositivity. 
Reweighting the sample to adjust for differences among individuals tested over time, we 
estimated the prevalence of current, TMA-positive SARS-CoV-2 infection within the population 
reached by outreach testing was 5.6% (2.9-10.6%), 7.4% (4.4-12.4%), 4.5% (2.6-7.5%), and 
8.0% (5.5-11.7%) over the periods of 16 July to 31 August, 1-30 September, 1-31 October, and 
1-30 November, respectively (Figure 5A). These results closely tracked patterns in the 
proportion of tests yielding positive results among all farmworkers tested by CSVS (Figure 1C). 
Over this period, we estimated between 2.0% (0.9-4.4%) and 6.4% (4.0-10.2%) prevalence of 
current SARS-CoV-2 infection among asymptomatic persons, and between 7.7% (3.7-15.8%) 
and 17.4% (10.4-29.3%) prevalence of current SARS-CoV-2 infection among individuals 
experiencing ≥1 symptom. Estimated seroprevalence increased from 10.5% (6.0-18.4%) to 
21.2% (16.6-27.4%) over the duration of the study, with similar results among symptomatic and 
asymptomatic individuals during each period (Figure 5B). 
 
DISCUSSION 
Among all adults tested for SARS-CoV-2 infection by clinics serving the Monterey 
County farmworker population, test positivity was 28% higher for farmworkers than for non-
farmworkers from the same communities. In comparison to the 6.1% overall test-positive 
fraction observed in Monterey County over the same period (26), test-positivity was 22.1% 
among farmworkers tested by CSVS. Within the cross-sectional study subpopulation, we 
identified sustained, high prevalence of infection, with TMA-positive results among 6.6% of 
individuals tested in the community and 18.7% of those tested in clinics. We estimated that 
roughly 10% of the farmworker population became infected over a 3-month period during the 
study, yielding ~21% seroprevalence by November, 2020. This seroprevalence is well above the 
5% seroprevalence noted among California adults in a large-scale assessment of blood specimens 
submitted for routine clinical screening or clinical management in September (27). A previous 
study in San Francisco likewise identified elevated infection risk in an urban, low-income and 
predominantly Latino population, with 6.0% prevalence of current infection among frontline 
workers and. 7.7% seroprevalence as of late April (28). Our findings demonstrate high infection 
risk among farmworkers during the ongoing pandemic.  
We identified a diverse array of symptoms, including gastrointestinal and other non-
respiratory symptoms, associated with SARS-CoV-2 infection. Among individuals found to be 
TMA-positive for current SARS-CoV-2 infection in our study, 41% did not report experiencing 
any symptoms in the two weeks preceding their test. Similar results have been reported in other 
studies (29). Importantly, individuals could have been pre-symptomatic at the time of their 
interview; additionally, asymptomatic individuals who seek testing may not represent the broader 
community, for instance if testing is triggered by known exposure SARS-CoV-2 exposure. The 
estimated 2-6% prevalence of infection among individuals without symptoms in the community 
suggests substantial risk of exposure to clinically-inapparent cases. Guidance issued for growers 
to screen farmworkers for fever or other COVID-19 symptoms is thus likely inadequate to 
prevent workplace infections (30). We also identified associations of higher antibody reactivity 
with current symptoms including loss of taste and smell, chest pain, and wheeze. Participants in 
our study likely experienced these symptoms in a persisting manner beyond the acute infectious 
stage, as seroconversion typically occurs 8-14 days following initial symptoms (31). While the 
clinical profile of “long COVID” remains to be fully clarified, these same symptoms have been 
identified as prominent complaints in prior studies along with fatigue, joint pain, and headache 
(32–34).  
Our study has limitations. We cannot verify how well our sample represents the 
farmworker population, many of whom are “hidden” from population statistical measures (35); 
our findings should be taken to represent individuals reached by testing. As we excluded 
individuals who did not speak Spanish or English sufficiently well to participate in the cross-
sectional study, our study likely under-represents indigenous populations (estimated at 13% of 
Salinas Valley farmworkers (12)). Roughly half of our cross-sectional study participants were 
enrolled in clinic-based testing, among whom infection prevalence was higher. For this reason, 
our statistical framework accounted for differences between clinic-based and outreach samples. 
Last, waning antibody titers from infections acquired early in the pandemic may have 
contributed to under-estimation of seroprevalence, in particular for individuals who experienced 
mild or asymptomatic infection (36). 
While Phase 1 vaccination programs have prioritized residents of long-term care facilities 
and healthcare workers, at the recommendation of the Advisory Committee on Immunization 
Practices (37), prioritization of differing essential workforce groups among Phase 2 recipients 
will be determined by states. Our study demonstrates high risk of SARS-CoV-2 infection and 
both acute and persisting symptoms of COVID-19 among farmworkers in California’s Salinas 
Valley, underscoring the urgency of preventive interventions for this population.  
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Table 1: Characteristics of the study population, by recruitment setting, Monterey County 
farmworkers cross-sectional study, July 16 to November 30 2020, N=1115. 
Attribute  All enrolled Clinic Outreach 
  n (%)1 n (%)1 n (%)1 
  N=1,115 N=565 N=550 
Age     
 18-29 277 (24.8) 140 (24.7)  137 (24.9) 
 30-39 274 (24.6) 136 (24.0) 138 (25.1) 
 40-49 298 (26.7) 163 (28.8) 135 (24.5) 
 50-59 200 (17.9) 90 (15.9) 110 (20.0) 
 ≥60 66 (5.9) 36 (6.4) 30 (5.5) 
Sex     
 Female 586 (52.6) 302 (53.5) 284 (51.6) 
 Male 529 (47.4) 263 (46.5) 266 (48.4) 
Country of birth     
 Mexico 929 (83.3) 486 (86.0) 443 (80.5) 
 US 142 (12.7) 49 (8.7) 93 (16.9) 
 Other 44 (3.9) 30 (5.3) 14 (2.5) 
Language spoken at home     
 Spanish 948 (85.0) 460 (81.4) 488 (88.7) 
 English 57 (5.1) 21 (3.7) 36 (6.5) 
 Indigenous language 110 (9.9) 84 (14.9) 26 (4.7) 
Education     
 Never attended 62 (5.6) 48 (8.5) 14 (2.5) 
 Some primary school 430 (38.6) 229 (40.5) 201 (36.5) 
 Primary school complete 238 (21.3) 119 (21.1) 119 (21.6) 
 Some high school 142 (12.7) 68 (12.0) 74 (13.5) 
 High school complete 242 (21.7) 100 (17.7) 142 (25.8) 
 No response 1 1 0 
Family income     
 <$25,000 560 (52.8) 291 (54.3) 269 (51.4) 
 $25,000-34,999 260 (24.6) 112 (20.9) 148 (28.3) 
 $35,000-49,999 162 (15.3) 86 (16.0) 76 (14.5) 
 ≥$50,000 77 (7.3) 47 (8.8) 30 (5.7) 
 No response 56 29 27 
Years in US     
 <15  262 (26.9) 157 (30.4) 105 (23.0) 
 15-19  194 (19.9) 110 (21.3) 84 (18.4) 
 20-29  299 (30.7) 141 (27.3) 158 (34.6) 
 ≥30 217 (22.3) 107 (20.7) 110 (24.1) 
 No answer 1 (0.1) 1 (0.2) 0 (0.0) 
H2A visa holder     
 Holds H2A visa 65 (6.8) 20 (4.0) 45 (10.0) 
 No response 155 56 99 
Community     
 Salinas 492 (44.1) 263 (46.5) 229 (41.6) 
 Northern Monterey County 73 (6.5) 18 (3.2) 55 (10.0) 
 Southern Monterey County 539 (48.3) 284 (50.3) 255 (46.4) 
 Outside Monterey County 11 (1.0) 0 (0.0) 11 
Household size     
 0 others 12 (1.1) 8 (1.4) 4 (0.7) 
 1-3 others 399 (35.8) 187 (33.1) 212 (38.6) 
 4-6 others 515 (46.2) 259 (45.8) 256 (46.5) 
 ≥7 others 189 (17.0) 111 (19.7) 78 (14.2) 
Children in household     
 Any children 836 (75.0) 440 (77.9) 396 (72.1) 
 No response 1 0 1 
Children attending school/daycare     
 Any children 85 (7.7) 57 (10.1) 28 (5.1) 
 No response 4 3 1 
Residential overcrowding     
 <2 persons/bedroom 490 (44.0) 224 (39.7) 266 (48.4) 
 ≥2 to <4 persons/bedroom 510 (45.7) 289 (51.2) 221 (40.2) 
 ≥4 persons/bedroom 115 (10.3) 52 (9.2) 63 (11.5) 
Ability to isolate at home if infected     
 Live alone or have >1 bedroom and bathroom 643 (57.7) 330 (58.4) 313 (56.9) 
Size of company     
 <25 workers 108 (11.5) 49 (10.1) 59 (12.9) 
 25-49 workers 132 (14.1) 67 (13.9) 65 (14.3) 
 50-499 workers 447 (47.6) 229 (47.4) 218 (47.8) 
 ≥500 workers 252 (26.8) 138 (28.9) 114 (25.0) 
 No answer 176 82 94 
Work setting     
 Indoors only 192 (17.2) 103 (18.3) 89 (16.2) 
 Outdoors only 849 (76.2) 425 (75.4) 424 (77.1) 
 Indoor/outdoor 73 (6.6) 36 (6.4) 37 (6.7) 
 No response 1 1 0 
Type of agricultural work     
 Working in the fields 830 (74.4) 416 (73.6) 414 (75.3) 
 Packing shed 133 (11.9) 65 (11.5) 68 (12.4) 
 Processing facility 64 (5.74) 34 (6.0) 30 (5.5) 
 Nursery 40 (3.6) 18 (3.2) 22 (4.0) 
 Truck driver 38 (3.4) 19 (3.4) 19 (3.5) 
 Packing truck 22 (1.97) 15 (2.7) 7 (1.3) 
 Other 21 (1.88) 12 (2.1) 9 (1.6) 
 No response 10 (0.9) 10 (1.8) 0 (0.0) 
Commute to work     
 Alone/with household members only 714 (65.6) 341 (61.6) 373 (69.9) 
 With non-household members 374 (34.4) 213 (38.4) 161 (30.1) 
 No response 27 11 16 
Body mass index     
 <18.5 (underweight0 4 (0.4) 2 (0.4) 2 (0.4) 
 18.5-24.9 (normal) 194 (17.8) 106 (19.4) 88 (16.2) 
 25-29.9 (overweight) 423 (38.9) 212 (38.9) 211 (38.9) 
 ≥30 (obese) 466 (42.9) 225 (41.3) 241 (44.5) 
 Not collected 28 20 8 
Smoking     
 Never smoked 907 (81.4) 460 (81.6) 447 (81.3) 
 Former smoker 158 (14.2) 86 (15.2) 72 (13.1) 
 Current smoker 49 (4.4) 18 (3.2) 31 (5.6) 
 No response 1 1 0 
Contact with ARI cases     
 None 971 (89.3) 449 (82.1) 522 (96.7) 
 At work only 66 (6.1) 54 (9.9) 12 (2.2) 
 At home only 44 (4.0) 38 (6.9) 6 (1.1) 
 At home and work 6 (0.6) 6 (1.1) 0 (0.0) 
 No response 28 18 10 
Attended gatherings     
 Attended in preceding 2 weeks 113 (10.2) 50 (8.9) 63 (11.5) 
 No response 2 1 1 
Recent COVID-19 symptoms     
 Symptoms in preceding 2 weeks 301 (27.2) 200 (35.8) 101 (18.4) 
 No response 7 0 7 
History of COVID-19 symptoms     
 Symptoms since pandemic started 457 (41.2) 266 (47.7) 191 (34.7) 
 No response 7 7 0 
SARS-CoV-2 infection     
 Positive TMA result 141 (12.7) 105 (18.7) 36 (6.6) 
 TMA result not available 4 2 2 
Prior SARS-CoV-2 infection     
 Positive antibody result 201 (19.0) 97 (18.4) 104 (19.5) 
 Antibody result not available 57 39 18 
Values in parentheses are the proportion, calculated excluding persons for whom data were not available. Clinic participants are those 
recruited on clinic premises, where they may have been seeking care for COVID-19 or any other cause. Outreach participants are those 
recruited at mobile testing operations in the community, who were not seeking medical care. 
Table 2: Prevalence of SARS-CoV-2 infection by transcription-mediated amplification assay, 
symptoms, and recruitment setting. 
 
  
Symptom Frequency of symptoms among all participants and test positivity among individuals with listed symptoms, n 
(%) 
 All participants Clinic participants Outreach participants 
 Frequency1 Infected2 Frequency1 Infected2 Frequency1 Infected2 
 N=1,108  N=558  N=550  
Non-productive 
cough 
68 (6.1) 31 (45.6) 47 (8.4) 26 (55.3) 21 (3.8) 5 (23.8) 
Productive cough 68 (6.1) 25 (37.3) 51 (9.1) 21 (42.0) 17 (3.1) 4 (23.5) 
Pain or pressure in 
the ears 
24 (2.2) 10 (41.7) 19 (3.4) 10 (52.6) 5 (0.9) 0 (0.0) 
Blocked nose 62 (5.6) 22 (36.1) 50 (9.0) 19 (38.8) 12 (2.2) 3 (25.0) 
Runny nose 78 (7.0) 24 (31.2) 56 (10.0) 18 (32.7) 22 (4.0) 6 (27.3) 
Sneezing 95 (8.6) 21 (22.3) 61 (10.9) 16 (26.7) 34 (6.2) 5 (14.7) 
Watery eyes 57 (5.1) 14 (25.0) 48 (8.6) 14 (29.8) 9 (1.6) 0 (0.0) 
Hoarseness 49 (4.4) 19 (38.8) 42 (7.5) 17 (40.5) 7 (1.3) 2 (28.6) 
Self-reported fever3 56 (5.1) 33 (58.9) 47 (8.4) 29 (61.7) 9 (1.6) 4 (44.4) 
Sweating 48 (4.3) 22 (45.8) 40 (7.2) 20 (50.0) 8 (1.5) 2 (25.0) 
Chills 74 (6.7) 35 (47.3) 63 (11.3) 33 (52.4) 11 (2.0) 2 (18.2) 
Headache 147 (13.3) 46 (31.5) 100 (17.9) 39 (39.4) 47 (8.5) 7 (14.9) 
Tickle in throat 49 (4.4) 17 (34.7) 36 (6.5) 15 (41.7) 13 (2.4) 2 (15.4) 
Sore throat 103 (9.3) 32 (31.1) 78 (14.0) 29 (37.2) 25 (4.5) 3 (12.0) 
Myalgia 97 (8.8) 44 (45.8) 79 (14.2) 40 (51.3) 18 (3.3) 4 (22.2) 
Chest pain 26 (2.3) 11 (42.3) 21 (3.8) 10 (47.6) 5 (0.9) 1 (20.0) 
Sinus pain 17 (1.5) 7 (41.2) 14 (2.5) 7 (50.0) 3 (0.5) 0 (0.0) 
Swollen glands 18 (1.6) 5 (27.8) 11 (2.0) 5 (45.5) 7 (1.3) 0 (0.0) 
Loss of appetite 38 (3.4) 21 (55.3) 32 (5.7) 18 (56.2) 6 (1.1) 3 (50.0) 
Difficulty breathing 34 (3.1) 18 (52.9) 27 (4.8) 16 (59.3) 7 (1.3) 2 (28.6) 
Wheezing 15 (1.4) 6 (40.0) 12 (2.2) 6 (50.0) 3 (0.5) 0 (0.0) 
Shortness of breath 22 (2.0) 18 (81.8) 19 (3.4) 16 (84.2) 3 (0.5) 2 (66.7) 
Diarrhea 40 (3.6) 15 (37.5) 33 (5.9) 14 (42.4) 7 (1.3) 1 (14.3) 
Nausea 39 (3.5) 13 (33.3) 32 (5.7) 13 (40.6) 7 (1.3) 0 (0.0) 
Stomach pain 47 (4.2) 15 (31.9) 34 (6.1) 12 (35.3) 13 (2.4) 3 (23.1) 
Trouble thinking 18 (1.6) 5 (27.8) 10 (1.8) 5 (50.0) 8 (1.5) 0 (0.0) 
Fatigue 94 (8.5) 33 (35.5) 70 (12.5) 31 (44.9) 24 (4.4) 2 (8.3) 
Loss of sense of taste 33 (3.0) 22 (66.7) 26 (4.7) 18 (69.2) 7 (1.3) 4 (57.1) 
Loss of sense of 
smell 
32 (2.9) 22 (68.8) 25 (4.5) 19 (76.0) 7 (1.3) 3 (42.9) 
Pain or pressure in 
the eyes 
25 (2.3) 6 (24.0) 16 (2.9) 6 (37.5) 9 (1.6)  0 (0.0) 
No response 7  7  0  
Any symptom 301 (27.2) 83 (27.7) 200 (35.8) 68 (34.2) 101 (18.4) 15 (14.9) 
No symptoms 807 (72.8) 57 (7.1) 358 (64.2) 36 (10.1) 449 (81.6) 21 (4.7) 
Values in parentheses are the proportion, calculated excluding persons for whom data were not available. Clinic participants are those 
recruited on clinic premises, where they may have been seeking care for COVID-19 or any other cause. Outreach participants are those 
recruited at mobile testing operations in the community, who were not seeking medical care. 
1Proportions are computed among all tested 
2Proportions indicate the prevalence of current, TMA-positive infection among those with the indicated symptom(s) in the last two weeks. 
3Participants were not asked to verify whether they recorded their body temperature. 
Figure 1: SARS-CoV-2 diagnoses at CSVS. We plot two-week moving averages of the (A) 
number of patients tested by CSVS; (B) the number of SARS-CoV-2 infection diagnoses; and 
(C) the proportion of tests yielding positive results, with shading for 95% confidence intervals. 
Below, we plot age- and sex- stratified test-positive fractions for (D) female and (E) male 
patients. Vertical lines in panels A-C indicate the date of initiation of the cross-sectional study 



























































































































































































































Figure 2: Participants recruited into the cross-sectional study. We indicate the number of patients 
recruited at each participating CSVS clinic as well as the outreach venues where participants 
were recruited in the community. We indicate the number and proportion of participants 
reporting symptoms or exposure to a known or suspected COVID-19 case in the prior two weeks 













Figure 3: Association of symptoms with current TMA-positive infection. We illustrate the 
prevalence of each symptom in the two weeks preceding testing among individuals who tested 
positive and negative for SARS-CoV-2 infection via TMA, as well as the adjusted odds ratio 
(aOR) conveying the association of each symptom with current infection. We obtain aORs via 
logistic regression, controlling for age group, sex, and recruitment venue (clinic-based or 
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Figure 4: Anti-spike IgG antibody reactivity and association with recalled symptoms. We plot 
distributions of antibody reactivity (optical density, OD) among individuals who (A) reported 
experiencing or did not report experiencing various symptoms potentially associated with 
COVID-19 since December, 2019; (B) reported experiencing or did not report experiencing 
various symptoms in the two weeks before enrollment (data not shown for symptoms with 
p>0.1); and (C) had a positive or negative SARS-CoV-2 TMA test result at the enrollment visit. 
Reported p-values are measured in logistic regression models with the occurrence of each 
symptom as the outcome and antibody ELISA OD values (log-transformed) as predictors, with 




















































































































































































































































































2B. Symptoms in past 2 weeks C. Current infection
Figure 5: Community prevalence of SARS-CoV-2 positivity by TMA and seropositivity over 
time. We plot estimated prevalence of SARS-CoV-2 infection and seropositivity in samples 
reweighted to correct for differences in the population seeking testing over the course of the 












































































B. Anti−SARS−CoV−2 IgG ELISA
Symptomatic
Asymptomatic
All
